Literature DB >> 18667503

Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection.

Henry Radziewicz1, Chris C Ibegbu, Huiming Hon, Melissa K Osborn, Kamil Obideen, Mohammad Wehbi, Gordon J Freeman, Jeffrey L Lennox, Kimberly A Workowski, Holly L Hanson, Arash Grakoui.   

Abstract

A majority of patients infected with hepatitis C virus (HCV) do not sustain an effective T-cell response, and viremia persists. The mechanism leading to failure of the HCV-specific CD8(+) T-cell response in patients developing chronic infection is unclear. We investigated apoptosis susceptibility of HCV-specific CD8(+) T cells during the acute and chronic stages of infection. Although HCV-specific CD8(+) T cells in the blood during the acute phase of infection and in the liver during the chronic phase were highly activated and expressed an effector phenotype, the majority was undergoing apoptosis. In contrast, peripheral blood HCV-specific CD8(+) T cells during the chronic phase expressed a resting memory phenotype. Apoptosis susceptibility of HCV-specific CD8(+) T cells was associated with very high levels of programmed death-1 (PD-1) and low CD127 expression and with significant functional T-cell deficits. Further evaluation of the "death phase" of HCV-specific CD8(+) T cells during acute HCV infection showed that the majority of cells were dying by a process of cytokine withdrawal, mediated by activated caspase 9. Contraction during the acute phase occurred rapidly via this process despite the persistence of the virus. Remarkably, in the chronic phase of HCV infection, at the site of infection in the liver, a substantial frequency of caspase 9-mediated T-cell death was also present. This study highlights the importance of cytokine deprivation-mediated apoptosis with consequent down-modulation of the immune response to HCV during acute and chronic infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18667503      PMCID: PMC2566282          DOI: 10.1128/JVI.01075-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  The liver as a site of T-cell apoptosis: graveyard, or killing field?

Authors:  I N Crispe; T Dao; K Klugewitz; W Z Mehal; D P Metz
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

2.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

Authors:  M F Callan; C Fazou; H Yang; T Rostron; K Poon; C Hatton; A J McMichael
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

3.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

Authors:  J T Gerlach; H M Diepolder; M C Jung; N H Gruener; W W Schraut; R Zachoval; R Hoffmann; C A Schirren; T Santantonio; G R Pape
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

5.  CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection.

Authors:  Nadia Alatrakchi; Camilla S Graham; Qi He; Kenneth E Sherman; Margaret James Koziel
Journal:  J Infect Dis       Date:  2005-01-28       Impact factor: 5.226

Review 6.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection.

Authors:  Simon M Rushbrook; Scott M Ward; Esther Unitt; Sarah L Vowler; Michaela Lucas; Paul Klenerman; Graeme J M Alexander
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

8.  Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood.

Authors:  Kai Bratke; Michael Kuepper; Britta Bade; J Christian Virchow; Werner Luttmann
Journal:  Eur J Immunol       Date:  2005-09       Impact factor: 5.532

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

View more
  46 in total

1.  IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus.

Authors:  Jung-Sik Kim; Bon-A Cho; Ji Hyun Sim; Kamini Shah; Connie M Woo; Eun Bong Lee; Dong-Sup Lee; Jae Seung Kang; Wang Jae Lee; Chung-Gyu Park; Joe Craft; Insoo Kang; Hang-Rae Kim
Journal:  Rheumatology (Oxford)       Date:  2012-06-01       Impact factor: 7.580

Review 2.  Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.

Authors:  Juan-Ramón Larrubia; Elia Moreno-Cubero; Joaquín Miquel; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 3.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

4.  HCV-specific interleukin-21+CD4+ T cells responses associated with viral control through the modulation of HCV-specific CD8+ T cells function in chronic hepatitis C patients.

Authors:  Guohua Feng; Ji-Yuan Zhang; Qing-Lei Zeng; Lei Jin; Junliang Fu; Bin Yang; Ying Sun; Tianjun Jiang; Xiangsheng Xu; Zheng Zhang; Jinhong Yuan; Liyuan Wu; Fu-Sheng Wang
Journal:  Mol Cells       Date:  2013-10-22       Impact factor: 5.034

5.  A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection.

Authors:  John A Mengshol; Lucy Golden-Mason; Tomohiro Arikawa; Maxwell Smith; Toshiro Niki; Ryan McWilliams; Jessica A Randall; Rachel McMahan; Michael A Zimmerman; Manu Rangachari; Evgenia Dobrinskikh; Pierre Busson; Stephen J Polyak; Mitsuomi Hirashima; Hugo R Rosen
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

6.  Rare birds in North America: acute hepatitis C cohorts.

Authors:  Andrea L Cox; Kimberly Page; Julie Bruneau; Naglaa H Shoukry; Georg M Lauer; Arthur Y Kim; Hugo R Rosen; Hank Radziewicz; Arash Grakoui; Daniel S Fierer; Andrea D Branch; David E Kaplan; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2008-12-04       Impact factor: 22.682

7.  Liver is able to activate naïve CD8+ T cells with dysfunctional anti-viral activity in the murine system.

Authors:  John R Lukens; Joseph S Dolina; Taeg S Kim; Robert S Tacke; Young S Hahn
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

8.  T-cell dysfunction and inhibitory receptors in hepatitis C virus infection.

Authors:  Jino Lee; William I Suh; Eui-Cheol Shin
Journal:  Immune Netw       Date:  2010-08-31       Impact factor: 6.303

9.  PD-1 expression on peripheral CD8+ TEM/TEMRA subsets closely correlated with HCV viral load in chronic hepatitis C patients.

Authors:  Tao Shen; Jiajia Zheng; Chunhui Xu; Jia Liu; Weidong Zhang; Fengmin Lu; Hui Zhuang
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

Review 10.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.